Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

22. Stiripentol add-on therapy for focal refractory epilepsy.

Stiripentol add-on therapy for focal refractory epilepsy. BACKGROUND: This is an updated version of the Cochrane review last published in 2015 (Issue 10). For nearly 30% of people with epilepsy, seizures are not controlled by current treatments. Stiripentol is a new antiepileptic drug (AED) that was developed in France and was approved by the European Medicines Agency (EMA) in 2007 for the treatment of Dravet syndrome as an adjunctive therapy with valproate and clobazam, with promising effects (...) . OBJECTIVES: To evaluate the efficacy and tolerability of stiripentol as add-on treatment for people with focal refractory epilepsy who are taking AEDs. SEARCH METHODS: For the latest update, we searched the following databases on 21 August 2017: Cochrane Epilepsy Specialized Register, CENTRAL , MEDLINE, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP). We contacted Biocodex (the manufacturer of stiripentol) and epilepsy experts to identify published, unpublished

Cochrane2018

23. Clonazepam add-on therapy for refractory epilepsy in adults and children.

Clonazepam add-on therapy for refractory epilepsy in adults and children. BACKGROUND: Epilepsy affects about 50 million people worldwide, nearly a quarter of whom have drug-refractory epilepsy. People with drug-refractory epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life. OBJECTIVES: To assess the efficacy and tolerability of clonazepam when used as an add-on therapy for adults and children with refractory focal onset (...) or generalised onset epileptic seizures, when compared with placebo or another antiepileptic agent. SEARCH METHODS: We searched the following databases on 14 September 2017: Cochrane Epilepsy Group Specialized Register, Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 14 September 2017), ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP). SELECTION CRITERIA: Double-blind randomised

Cochrane2018

24. Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial

Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} For adults with epilepsy and persistent seizures, a 2-day group course increased their self-confidence, but did not change their quality of life 12 months later. {{author}} {{($index , , , , , , , , , , , , & . Leone Ridsdale 1, * , Alison McKinlay 1 , Gabriella Wojewodka 1 , Emily J Robinson 2 , Iris Mosweu 3 , Sarah J Feehan 1 , Adam J Noble 4 , Myfanwy Morgan 5 , Stephanie J C Taylor

NIHR HTA programme2018

25. Epilepsy in Children After Pandemic Influenza Vaccination

Epilepsy in Children After Pandemic Influenza Vaccination 29449342 2018 02 16 1098-4275 2018 Feb 15 Pediatrics Pediatrics Epilepsy in Children After Pandemic Influenza Vaccination. e20170752 10.1542/peds.2017-0752 To determine if pandemic influenza vaccination was associated with an increased risk of epilepsy in children. Information from Norwegian registries from 2006 through 2014 on all children <18 years living in Norway on October 1, 2009 was used in Cox regression models to estimate hazard (...) ratios for incident epilepsy after vaccination. A self-controlled case series analysis was used to estimate incidence rate ratios in defined risk periods after pandemic vaccination. In Norway, the main period of the influenza A subtype H1N1 pandemic was from October 2009 to December 2009. On October 1, 2009, 1 154 113 children <18 years of age were registered as residents in Norway. Of these, 572 875 (50.7%) were vaccinated against pandemic influenza. From October 2009 through 2014 there were 3628

EvidenceUpdates2018

26. Rufinamide add-on therapy for refractory epilepsy.

Rufinamide add-on therapy for refractory epilepsy. BACKGROUND: Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often requiring treatment with a combination of AEDs. In this review, we (...) summarised the current evidence regarding rufinamide, a novel anticonvulsant medication, which, as a triazole derivative, is structurally unrelated to any other currently used anticonvulsant medication, when used as an add-on treatment for refractory epilepsy. In January 2009, rufinamide was approved by the US Food and Drug Administration for treatment of children four years of age and older with Lennox-Gastaut syndrome. It is also approved as an add-on treatment for adults and adolescents with focal

Cochrane2018

27. A range of anti-epilepsy drugs are effective as first-line treatment

A range of anti-epilepsy drugs are effective as first-line treatment NIHR DC | Signal - A range of anti-epilepsy drugs are effective as first-line treatment Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal A range of anti-epilepsy drugs are effective as first-line treatment Published on 12 September 2017 Lamotrigine and levetiracetam are emerging as first-line treatments for epilepsy, which people may be more likely to keep taking than carbamazepine. Reducing the risk (...) of adverse events and treatment withdrawal is important when selecting an anti-epilepsy drug as it usually will need to be taken long-term. This study reviewed evidence on anti-epilepsy drugs in adults and children. The drugs were compared directly or indirectly with each other. The main outcome of interest was time to withdrawal from treatment, which indicates effectiveness and tolerability. The findings support NICE recommendations to use carbamazepine or lamotrigine as first-line therapies

NIHR Dissemination Centre2018

28. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence 29511052 2018 03 07 1468-330X 2018 Mar 06 Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. jnnp-2017-317168 10.1136/jnnp-2017-317168 Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic (...) as adjuvant treatment in paediatric-onset drug-resistant epilepsy may reduce seizure frequency. Existing RCT evidence is mostly in paediatric samples with rare and severe epilepsy syndromes; RCTs examining other syndromes and cannabinoids are needed. CRD42017055412. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Stockings Emily E National Drug and Alcohol Research

EvidenceUpdates2018

29. Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study

Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study 29490912 2018 04 04 1526-632X 90 13 2018 Mar 27 Neurology Neurology Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study. e1111-e1118 10.1212/WNL.0000000000005210 To investigate the association between epilepsy and antiepileptic drugs and serious transport accidents requiring emergency care or resulting in death. We identified 29,220 individuals 18 years or older (...) with epilepsy without cerebral palsy or intellectual disability and 267,637 matched controls using Swedish registers. This nationwide cohort was followed from 2006 to 2013 for serious transport accidents. We used Cox regression to analyze the risk of serious transport accidents between individuals with epilepsy and matched controls, and then stratified Cox regression to compare the risk during periods of medication with the risk during nonmedication period within the same individual with epilepsy. We

EvidenceUpdates2018

30. Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy.

Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy. BACKGROUND: In juvenile myoclonic epilepsy, data are limited on the genetic basis of networks promoting convulsions with diffuse polyspikes on electroencephalography (EEG) and the subtle microscopic brain dysplasia called microdysgenesis. METHODS: Using Sanger sequencing, we sequenced the exomes of six members of a large family affected with juvenile myoclonic epilepsy and confirmed cosegregation in all 37 family members. We (...) and conducted video-EEG studies in mice lacking a copy of Ick. RESULTS: A variant, K305T (c.914A→C), cosegregated with epilepsy or polyspikes on EEG in 12 members of the family affected with juvenile myoclonic epilepsy. We identified 21 pathogenic ICK variants in 22 of 310 additional patients (7%). Four strongly linked variants (K220E, K305T, A615T, and R632X) impaired mitosis, cell-cycle exit, and radial neuroblast migration while promoting apoptosis. Tonic-clonic convulsions and polyspikes on EEG

NEJM2018

31. Care delivery and self-management strategies for children with epilepsy.

Care delivery and self-management strategies for children with epilepsy. BACKGROUND: In response to criticism that epilepsy care for children has little impact, healthcare professionals and administrators have developed various service models and strategies to address perceived inadequacies. OBJECTIVES: To assess the effects of any specialised or dedicated intervention for epilepsy versus usual care in children with epilepsy and in their families. SEARCH METHODS: We searched the Cochrane (...) Epilepsy Group Specialized Register (27 September 2016), the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 9) in the Cochrane Library, MEDLINE (1946 to 27 September 2016), Embase (1974 to 27 September 2016), PsycINFO (1887 to 27 September 2016) and CINAHL Plus (1937 to 27 September 2016). In addition, we also searched clinical trials registries for ongoing or recently completed trials, contacted experts in the field to seek information on unpublished and ongoing studies, checked

Cochrane2018

32. Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial

Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial 29444968 2018 03 13 1526-632X 90 11 2018 Mar 13 Neurology Neurology Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial. e963-e970 10.1212/WNL.0000000000005109 To evaluate the effect of a stress-reduction intervention in participants with medication-resistant epilepsy. Adults with medication-resistant focal epilepsy (n = 66) were recruited from 3 centers (...) . Both PMR and the focused-attention groups showed reduced seizure frequency compared to baseline in participants with medication-resistant focal seizures, although the 2 treatments did not differ. PMR was more effective than focused attention in reducing self-reported stress. NCT01444183. © 2018 American Academy of Neurology. Haut Sheryl R SR From Montefiore-Einstein Epilepsy Center (S.R.H.) and Departments of Neurology (S.R.H., R.B.L.) and Epidemiology and Population Health (R.B.L.), Montefiore

EvidenceUpdates2018

33. Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT

Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The competency framework conferred no clinical benefit, compared to treatment as usual, in reducing seizure severity in adults with epilepsy and learning disability. {{author}} {{($index , , , , , , , , , , , , , , , & . Howard Ring 1, 2, 3, * , James Howlett 4 , Mark Pennington 5 , Christopher Smith 1 , Marcus Redley 1, 3, 6 , Caroline Murphy 7 , Roxanne Hook 1

NIHR HTA programme2018

34. Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy

Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy Redirecting

Kidney international reports2018 Full Text: Link to full Text with Trip Pro

35. Five and 10 minute Apgar scores and risks of cerebral palsy and epilepsy: population based cohort study in Sweden.

Five and 10 minute Apgar scores and risks of cerebral palsy and epilepsy: population based cohort study in Sweden. OBJECTIVE: To investigate associations between Apgar score at five and 10 minutes across the entire range of score values (from 0 to 10) and risks of childhood cerebral palsy or epilepsy, and to analyse the effect of changes in Apgar scores from five to 10 minutes after birth in infants born ≥37 completed weeks. DESIGN, SETTING, AND PARTICIPANTS: Population based cohort study (...) in Sweden, including 1 213 470 non-malformed live singleton infants, born at term between 1999 and 2012. Data on maternal and pregnancy characteristics and diagnoses of cerebral palsy and epilepsy were obtained by individual record linkages of nationwide Swedish registries. EXPOSURES: Apgar scores at five and 10 minutes. MAIN OUTCOME MEASURE: Cerebral palsy and epilepsy diagnosed up to 16 years of age. Adjusted hazard ratios were calculated, along with 95% confidence intervals. RESULTS: 1221 (0.1

BMJ2018

37. Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised prospective clinical trial

Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised prospective clinical trial 29273691 2017 12 23 1468-330X 2017 Dec 22 Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised (...) prospective clinical trial. jnnp-2017-316311 10.1136/jnnp-2017-316311 To compare the effects of different surgical approaches for selective amygdalohippocampectomy in patients with pharmacoresistant mesial temporal lobe epilepsy with regard to the neuropsychological outcome and to replicate an earlier study employing a matched-pair design. 47 patients were randomised to subtemporal versus transsylvian approaches. Memory, language, attentional and executive functions were assessed before and 1 year after

EvidenceUpdates2018

39. Management of epilepsy in adults with intellectual disability

Management of epilepsy in adults with intellectual disability CR203 Browser does not support script. Browser does not support script. Improving the lives of people with mental illness Browser does not support script. CR203. Management of epilepsy in adults with intellectual disability Price: £0.00 Approved: Apr 2017 Published: May 2017 Status: current Number of pages: 49 Review by: 2022 This report is available online-only. There are no print copies to buy. This long-awaited report offers (...) an important step towards clarifying the role of the psychiatrist in ID in the management of epilepsy. The proposed tiered system of professional competency gives psychiatrists the option to identify their role in care provision and ensures a framework for training. It provides a structure from which a competency evaluation can be developed. The vision should be for all psychiatrists working with people with ID to have training and certification to one of the three levels of competency (Bronze, Silver

Royal College of Psychiatrists2018

40. Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability

Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability CR206 Browser does not support script. Browser does not support script. Improving the lives of people with mental illness Browser does not support script. CR206. Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability Price: £0.00 Approved: Aug 2017 Published: Oct 2017 Status: current Number of pages: 60 Review by: 2022 This report addresses the extremely important area (...) of epilepsy in the field of intellectual disability (ID), also known as learning disability. Epilepsy and ID are two conditions that carry stigma and can lead to social isolation. An individual who experiences both these problems faces huge challenges. Contents Working group Foreword Scope of this report Executive summary Guiding principles Background Objectives and methodology Summary of evidence Evidence of the use of specific AEDs in people with ID Choosing the most appropriate AED Prescribing guidance

Royal College of Psychiatrists2018